Empagliflozin, commercially known as Jardiance, is at the forefront of contemporary type 2 diabetes management. The prevalence of type 2 diabetes has been a growing concern globally, with the World Health Organization reporting a significant increase in cases over the past few decades. As of the last review, an estimated 422 million adults